Orion Portfolio Solutions LLC Acquires 9,170 Shares of Insmed Incorporated (NASDAQ:INSM)

Orion Portfolio Solutions LLC grew its holdings in Insmed Incorporated (NASDAQ:INSM) by 48.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,087 shares of the biopharmaceutical company’s stock after purchasing an additional 9,170 shares during the period. Orion Portfolio Solutions LLC’s holdings in Insmed were worth $2,050,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. V Square Quantitative Management LLC bought a new position in shares of Insmed in the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter. Finally, CWM LLC lifted its stake in Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 155 shares during the last quarter.

Insmed Stock Down 2.9 %

INSM stock opened at $72.05 on Friday. The company’s 50 day moving average is $72.40 and its 200 day moving average is $70.82. The stock has a market cap of $12.89 billion, a price-to-earnings ratio of -12.98 and a beta of 1.10. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same period in the prior year, the company earned ($1.10) earnings per share. The business’s revenue was up 18.1% compared to the same quarter last year. Sell-side analysts predict that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on INSM shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Finally, Bank of America raised their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.